<DOC>
	<DOCNO>NCT01762592</DOCNO>
	<brief_summary>Study WX-20-002 confirm diagnostic efficacy safety PET/CT scan use Iodine ( 124I ) Girentuximab perform diagnostic work-up patient indeterminate cT1-renal mass .</brief_summary>
	<brief_title>REDECT 2 : REnal Masses : Pivotal Trial DEteCT Clear Cell Renal Cell Carcinoma With PET/CT</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<criteria>1 . â‰¥18 year age . 2 . Presence indeterminate cT1 renal mass screen CT without contrast MRI without contrast ( MRI CT contraindicate ) . 3 . Negative serum pregnancy test ; perform female patient childbearing potential within 24 hour prior receive investigational product . 4 . Recovered toxicity prior therapy grade 1 better . 5 . Able take oral medication ( KI ) . 6 . Written inform consent available . 1 . Renal mass know metastasis another primary tumor . 2 . Known histology renal mass ( e.g . biopsy ) . 3 . Active nonrenal malignancy require therapy time frame individual patient study participation . 4 . Chemotherapy , radiotherapy , immunotherapy within 4 week prior Iodine ( 124I ) Girentuximab infusion Day 0 continue adverse effect ( &gt; grade 1 ) therapy . 5 . Exposure murine proteins chimeric antibody within last 5 year . 6 . Intercurrent medical condition may limit patient 's study participation compliance . 7 . History autoimmune hepatitis . 8 . Mental impairment may compromise ability give informed consent comply requirement study . 9 . Participation clinical trial involve another investigational product within 4 week prior enrollment . 10 . Women pregnant breastfeeding . 11 . Contraindication KI intake ( see package insert/Appendix VI ) . 12 . Hyperthyroidism , Grave 's Disease . 13 . Contraindication PET/CT .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>